Physiological Actions of GLP-1s

GLP-1 shows numerous actions in different tissues and a broad therapeutic potential. The main actions of GLP-1 are to stimulate insulin secretion and to inhibit glucagon secretion, thereby contributing to limit postprandial glucose excursions. GLP-1 also causes weight loss by increasing satiety. In addition, GLP-1 also inhibits gastrointestinal motility and secretion and thus acts as an enterogastrone and part of the “ileal brake“ mechanism. GLP-1 New Drug R&D Service Medicilon provides GLP-1 drug discovery, CMC research (API formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1 drugs (3 approved by FDA and NMPA，1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development.